DE69334246D1 - Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome - Google Patents

Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome

Info

Publication number
DE69334246D1
DE69334246D1 DE69334246T DE69334246T DE69334246D1 DE 69334246 D1 DE69334246 D1 DE 69334246D1 DE 69334246 T DE69334246 T DE 69334246T DE 69334246 T DE69334246 T DE 69334246T DE 69334246 D1 DE69334246 D1 DE 69334246D1
Authority
DE
Germany
Prior art keywords
diabetes
diagnosis
treatment
methods
man syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334246T
Other languages
English (en)
Inventor
Steinunn Baekkeskov
Wiltrud Richter
Mark Namchuk
Yuguang Shi
John Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69334246D1 publication Critical patent/DE69334246D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
DE69334246T 1992-12-03 1993-12-02 Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome Expired - Lifetime DE69334246D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98493592A 1992-12-03 1992-12-03
PCT/US1993/011705 WO1994012529A1 (en) 1992-12-03 1993-12-02 Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome

Publications (1)

Publication Number Publication Date
DE69334246D1 true DE69334246D1 (de) 2008-12-24

Family

ID=25531040

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69334246T Expired - Lifetime DE69334246D1 (de) 1992-12-03 1993-12-02 Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome

Country Status (7)

Country Link
US (3) US5691448A (de)
EP (1) EP0701569B1 (de)
JP (2) JP4242446B2 (de)
DE (1) DE69334246D1 (de)
DK (1) DK0701569T3 (de)
ES (1) ES2318847T3 (de)
WO (1) WO1994012529A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
ES2318847T3 (es) * 1992-12-03 2009-05-01 The Regents Of The University Of California Metodos y reactivos mejorados para el diagnostico y el tratamiento de diabetes y del sindrome de stiff man.
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
CN1112933A (zh) 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 抗原特异性活化t淋巴细胞，其检测和用途
DE69637130T2 (de) 1995-02-20 2008-02-21 The Walter And Eliza Hall Institute Of Medical Research, Parkville Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
AU706774B2 (en) * 1995-02-20 1999-06-24 Walter And Eliza Hall Institute Of Medical Research, The Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US5853723A (en) * 1995-09-21 1998-12-29 University Of Utah Research Foundation Targeting of peg antibody conjugates to islet cells
JPH09203734A (ja) * 1996-01-26 1997-08-05 Sumitomo Electric Ind Ltd 抗血清、抗体、リガンド及びそれらの検出方法
US5821334A (en) * 1996-01-26 1998-10-13 Vanderbilt University Insulin-dependent diabetes mellitus-specific chimeric polypeptides
US6982323B1 (en) * 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
ES2283084T3 (es) * 1997-12-23 2007-10-16 Alexion Pharmaceuticals, Inc. Proteinas quimericas para el tratamiento de diabetes.
JP3926626B2 (ja) * 1999-08-18 2007-06-06 キム・ホヨン 免疫学的寛容−誘導物質
EP1149914B1 (de) * 2000-04-10 2008-06-18 Labor Dr. Merk und Kollegen GmbH Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
FI116198B (fi) * 2001-07-16 2005-10-14 Valtion Teknillinen Polypeptidien immobilisointimenetelmä
US20050130245A1 (en) * 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
GB0128583D0 (en) * 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
AU2003226899A1 (en) * 2002-03-20 2003-09-29 Syddansk Universitet Human diabetes-mediating proteins
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EP2377882A1 (de) * 2004-10-28 2011-10-19 University of Pittsburgh of the Commonwealth System of Higher Education Peripher verabreichte Gentherapie mit Glutaminsäure-Decarboxylase gegen Schmerzen aufgrund einer Rückenmarksverletzung
WO2006098485A1 (ja) * 2005-03-15 2006-09-21 Tokyo University Of Science グルタミン酸脱炭酸酵素変異体
JP5405111B2 (ja) * 2005-09-26 2014-02-05 ウルリヒ ルース Ｔｓｈ受容体及び新規ｔｓｈ受容体キメラに対する自己免疫抗体検出方法
WO2007114959A2 (en) * 2006-04-04 2007-10-11 University Of Toledo Altered peptide ligands of gad65
EP2146741A4 (de) * 2007-04-24 2010-08-04 Diamyd Therapeutics Ab Medikamente und verfahren zur behandlung von autoimmunerkrankungen und krebs
WO2009097425A2 (en) * 2008-01-29 2009-08-06 Spring Bioscience Corporation Method for detecting truncated molecules
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
EP2836845B1 (de) 2012-04-13 2018-05-09 DiabetOmics, Inc. Biomarker für schwangerschaftsdiabetes
CN103788183B (zh) * 2012-10-30 2016-04-13 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098667A (zh) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661828B2 (en) * 1990-08-17 1995-08-10 University Of Florida Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus
ATE268908T1 (de) * 1990-09-07 2004-06-15 Univ California Verfahren zur diagnose und behandlung von diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
ES2318847T3 (es) * 1992-12-03 2009-05-01 The Regents Of The University Of California Metodos y reactivos mejorados para el diagnostico y el tratamiento de diabetes y del sindrome de stiff man.

Also Published As

Publication number Publication date
EP0701569B1 (de) 2008-11-12
JPH08504406A (ja) 1996-05-14
JP4242446B2 (ja) 2009-03-25
US5998584A (en) 1999-12-07
US5849506A (en) 1998-12-15
JP2009100744A (ja) 2009-05-14
EP0701569A4 (de) 1997-08-20
EP0701569A1 (de) 1996-03-20
JP5190698B2 (ja) 2013-04-24
WO1994012529A1 (en) 1994-06-09
DK0701569T3 (da) 2009-02-23
ES2318847T3 (es) 2009-05-01
US5691448A (en) 1997-11-25

Similar Documents

Publication Publication Date Title
DE69334246D1 (de) Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
DE69307509T2 (de) Vorrichtung zur behandlung von herzfehlern
DE69725339D1 (de) Vorrichtung zur diagnose und behandlung von arrhythmien
DE58906894D1 (de) Einrichtung zur diagnostik und behandlung von nasenerkrankungen.
DE68904248T2 (de) Einrichtung zur behandlung von fluessigkeiten.
DE69525473D1 (de) Vorrichtung zur behandlung von blutgefässen
DE69034092D1 (de) Vorrichtung zur Behandlung von Proben
DE69720058D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE69726195D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE69015905T2 (de) Vorrichtung zur Behandlung von Flüssigkeiten.
ATA907182A (de) Einrichtung zur behandlung von blutgefaessen od.dgl.
DE3881315T2 (de) Nassentschwefelungsverfahren zur Behandlung von Abgasen.
DE3884200D1 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
DE69015830D1 (de) Gerät zur Behandlung einer Flüssigkeit und Methode für den Antrieb.
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
DE68910175T2 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE68911500D1 (de) Verfahren zur behandlung und diagnose einer ischämischer herzkrankheit.
ATE235056T1 (de) Verfahren zur diagnose und therapie von plattenepithelkarzinomen
DE69408394T2 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE3888684D1 (de) Behandlung und diagnose von klauenseuche unter verwendung der basischen protease von bacteroides nodosus.
DE68904322T2 (de) Einrichtung zur behandlung von gasen.
ATA84689A (de) Einrichtung zur behandlung von gasen
DE69011065D1 (de) Verfahren zur Behandlung von Nickel-Magnesium-Silikaterzen.
DE68912463D1 (de) Konditionierte insektizide mischungen und verfahren zur insektiziden behandlung.
DE69128642T2 (de) Immunadsorbens zur diagnose von epilepsie und der risikogruppe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition